Pfizer CEO shares his expectations for its coronavirus disease 2019 (COVID-19) vaccine approval; peer review results are in for AstraZeneca and Oxford University’s COVID-19 vaccine candidate; there are now competing legislative proposals on surprise medical billing protection.
With his company’s coronavirus disease 2019 (COVID-19) vaccine already being distributed in the United Kingdom, Pfizer CEO and Chairman Albert Bourla, DVM, PhD, seems confident about imminent approval from the FDA, reports Reuters, following an early-week meeting with a US vaccine advisory panel. During a press call yesterday, he also shared that Pfizer and BioNTech are collaborating on a newer vaccine that can withstand higher temperatures, possibly enabling easier distribution. Currently, the vaccine must be stored at -70°C, although the partners say it can also be stored at 2°C and 8°C.
The potential vaccine from AstraZeneca and Oxford may have hit a bump in the road, according to an article published online yesterday in The Lancet and Reuters. Despite reports of 90% efficacy, this newest study aimed to elucidate on what many called “a lack of information” following the partners’ announcement last month about their vaccine candidate, ChAdOx1 nCoV-19. These results, pooled from 4 ongoing trials, show an overall efficacy of 70.4%, which is above the FDA’s 50% minimum but far below the aforementioned 90%. The authors point out that more research is needed, especially because few data are available on the potential vaccine’s efficacy in older individuals.
A 2-year effort to arrive at an equitable solution to safeguard against excessive bills for routine medical care is mired in now-competing proposals, according to The Hill, despite concerted efforts from the House Energy and Commerce, House Education and Labor, and Senate Health, Education, Labor and Pensions committees. House Ways and Means Committee Chairman Richard Neal, D-Massachusetts, may be the lone holdout, reportedly being unwilling to concede any ground on his own proposal. Despite both sides agreeing that patients deserve protection against massive, unexpected bills, division remains on how much insurers will need to pay in the end.
Mental Health Diagnoses, Care Challenges Rise Among US Youth, Report Finds
April 26th 2024While behavioral health care utilization has been rising, the treatment landscape has been falling. New findings show that 20% of youths did not receive any form of treatment within 3 months of their initial behavioral health diagnosis.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Males With Hemophilia A Report Physical, Mental Burdens of Disease Regardless of Severity
April 25th 2024Self-reported data from adult and pediatric males with hemophilia A show that burden of the disease persists regardless of severity, highlighting a need for improved prophylactic treatment.
Read More
Insurance Coverage Limits JAKi Therapy Access for Patients With AA, Especially Non-White Populations
April 25th 2024A survey study showed major barriers to Janus kinase inhibitor (JAKi) therapy for patients with alopecia areata, especially for non-White patients who face higher rates of being uninsured and struggle more to afford the treatment.
Read More